Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batiraxcept combinations in advanced ccRCC
NCT04300140Phase 2Terminated
- Sponsor
- Aravive, Inc.
- Start
- Feb 2021
- Primary completion
- Aug 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC), sponsored by Aravive, Inc.. Started Feb 2021; status: terminated.
02
Drugs
batiraxcept
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04300140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300140.